文献速递细菌感染、耐药与抗菌药物

使用难治性耐药指数衡量各国抗生素耐药流行与抗生素可及性之间的失衡:范围综述与概念提议

Using a difficult-to-treat resistance index to gauge imbalance between countries' antibiotic resistance prevalence and access to antibiotics: a scoping review and concept proposal.
PubMed 文献 · Clin Microbiol Infect · 2025-03-01

该范围综述检索多个数据库,纳入2018年1月后使用「难治性耐药(DTR)」描述对全部一线抗生素耐药的细菌分离株的原创研究,共57项研究覆盖94个国家。DTR定义多未经修改使用,70%研究保留预后效用;作者提出DTR指数(DTRi),将抗生素可及性纳入DTR框架以估计各国对当地可用全部一线抗生素耐药的细菌分离株比例。

要点

  • DTR定义在57项研究、94个国家中使用,多未经修改且70%研究保留预后效用。
  • 各国一线抗生素可及性和新药出现随时间变化,固定DTR定义无法捕捉实际治疗选择。
  • 作者提出DTRi,可评估新药引入的临床影响并识别耐药-可及性失衡热点区域。

核心结论

  • DTRi可评估一国引入新药的临床影响,识别耐药-可及性失衡热点区域,并优化资源分配以改善抗生素耐药结局,尤其在资源匮乏人群。

研究设计与样本

  • 范围综述,检索Agricola、Embase、Global Index Medicus、PubMed、Scopus、Web of Science的BIOSIS和Core Collection。
  • 纳入标准为2018年1月后使用「难治性耐药」描述对全部一线抗生素(即全部β-内酰胺和氟喹诺酮类抗生素)耐药的细菌分离株的原创研究。
  • 使用Joanna Briggs Institute批判性评估工具评估偏倚风险,将研究分为流行病学、死亡率或抗生素有效性/疗效研究。

主要发现

  • DTR在57项研究中使用,覆盖94个国家。
  • DTR定义主要未经修改应用,并在70%的研究中保留预后效用。
  • 各国一线抗生素可及性差异和新药出现随时间变化影响实际治疗选择,固定DTR定义无法捕捉。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inferring the impact of antimicrobial resistance on patient outcomes is challenging, given the variability in antibiotic access across countries and over time. By denoting resistance to all highly safe and effective antibiotics, the difficult-to-treat resistance (DTR) definition offers a framework for such assessments globally. OBJECTIVES: This study aims to conduct a scoping review to understand the international adoption, scalability, and prognostic utility of DTR and enable solutions to incorporate antibiotic access into the DTR framework. METHODS: Data sources: Data sources included Agricola, Embase, Global Index Medicus, PubMed, Scopus, Web of Science: BIOSIS and Core Collection. STUDY ELIGIBILITY CRITERIA: Study eligibility criteria included original research publications occurring after January 2018 using the term 'difficult-to-treat resistance' to describe antimicrobial-resistant bacterial isolates demonstrating resistance to all first-line antibiotics (i.e. all β-lactam and fluoroquinolone antibiotics). ASSESSMENT OF RISK OF BIAS: Assessment of risk of bias included Joanna Briggs Institute critical appraisal tool. METHODS OF DATA SYNTHESIS: We assessed the overall themes of the included studies and classified them into epidemiological, mortality, or antibiotic effectiveness/efficacy studies. Semiquantitative results among studies evaluating the prevalence of resistant bacterial isolates and mortality were reported. We propose a 'DTR index' (DTRi) that extends beyond gram-negative bacteria and complements DTR by estimating national proportions of bacterial isolates resistant to all first-line antibiotics available specifically in that country. RESULTS: DTR was utilized in 57 studies spanning 94 countries. The DTR definition was predominantly applied unmodified and retained prognostic utility in 70% of studies. The variability in access to first-line antibiotics and emergence of newer agents across countries and over time influence practical treatment options that cannot be captured by 'fixed' DTR definitions underscoring the value of the proposed DTRi. CONCLUSIONS: The DTRi could appraise the clinical impact of introducing new agents in a country, identify hot zones of resistance-access imbalance, and optimize resource allocation to improve antibiotic resistance outcomes, especially in under-resourced populations.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Walker MK, Chishti EA, Yek C, et al. Using a difficult-to-treat resistance index to gauge imbalance between countries' antibiotic resistance prevalence and access to antibiotics: a scoping review and concept proposal. Clin Microbiol Infect. 2025. PMID: 40032082. doi:10.1016/j.cmi.2025.02.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。